BridgeBio Pharma, Inc. (BBIO)
65.35
+0.31
(+0.48%)
USD |
NASDAQ |
Oct 09, 16:00
65.99
+0.64
(+0.98%)
After-Hours: 20:00
BridgeBio Pharma Free Cash Flow (Quarterly) : -71.54M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -71.54M |
| March 31, 2026 | -197.35M |
| December 31, 2025 | -56.45M |
| September 30, 2025 | -112.44M |
| June 30, 2025 | -85.78M |
| March 31, 2025 | -200.83M |
| December 31, 2024 | -198.56M |
| September 30, 2024 | -182.30M |
| June 30, 2024 | 72.26M |
| March 31, 2024 | -221.03M |
| December 31, 2023 | -125.25M |
| September 30, 2023 | -145.66M |
| June 30, 2023 | -113.78M |
| March 31, 2023 | -144.33M |
| December 31, 2022 | -92.92M |
| September 30, 2022 | -135.92M |
| June 30, 2022 | -34.36M |
| Date | Value |
|---|---|
| March 31, 2022 | -162.61M |
| December 31, 2021 | -136.43M |
| September 30, 2021 | -163.02M |
| June 30, 2021 | -94.00M |
| March 31, 2021 | -152.73M |
| December 31, 2020 | -98.41M |
| September 30, 2020 | -132.23M |
| June 30, 2020 | -88.20M |
| March 31, 2020 | -88.40M |
| December 31, 2019 | -77.95M |
| September 30, 2019 | -47.88M |
| June 30, 2019 | -70.39M |
| March 31, 2019 | -62.50M |
| December 31, 2018 | -47.16M |
| September 30, 2018 | -38.93M |
| June 30, 2018 | -35.61M |
| March 31, 2018 | -33.13M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 292.04M |
| Pfizer Inc. | 302.00M |
| Ionis Pharmaceuticals, Inc. | 547.30M |
| BioMarin Pharmaceutical, Inc. | 133.86M |
| Vertex Pharmaceuticals, Inc. | 1.013B |